Acurx Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Matthew Keller from H.C. Wainwright reiterated a Buy rating on the stock and has a $31.00 price target.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Matthew Keller’s rating is based on several promising developments at Acurx Pharmaceuticals. The company has made significant strides in increasing the visibility of its lead compound, ibezapolstat (IBZ), through recent publications and presentations. This has helped raise awareness in both private and public sectors, which is crucial for its late-stage clinical development.
Additionally, Acurx is actively exploring financing and partnering opportunities to expedite the development of IBZ. The company’s financial position is bolstered by a recent warrant exercise, adding to its cash reserves. Furthermore, preclinical data presented at IDWeek ’25 highlighted IBZ’s unique microbiome-sparing properties, which could enhance its efficacy in treating difficult bacterial infections. These factors collectively contribute to Keller’s optimistic outlook and Buy rating for Acurx Pharmaceuticals.